



30+ YEARS OF  
PATIENT  
SUPPORT\*

RealSupport™  
REAL INFORMATION FROM REAL PATIENTS  
Only from Sandostatin® LAR Depot  
(octreotide acetate) for neuroendocrine neoplasms  
10mg • 20mg • 30mg

For more recipes, tips, and helpful resources,  
like us on [Facebook.com/SandostatinLARDepot](https://www.facebook.com/SandostatinLARDepot)

*This recipe was created by our RealSupport™ nutritionist especially for our members. Remember, please talk to your health care provider to determine if this recipe or any other food is appropriate for you.*

Links to: <https://www.facebook.com/SandostatinLARDepot>

# LEEK AND GRUYÈRE FRITTATA

 Prep time: 5 minutes

 Cook time: 25 minutes

 Ready in: 30 minutes

## Ingredients

- 2 tablespoons unsalted butter substitute
- 1 tablespoon olive oil
- 3 leeks, white and light-green parts only, halved and thinly sliced
- 1 teaspoon kosher salt
- ½ teaspoon black pepper
- 8 large eggs
- ¼ cup low-fat milk
- 1 cup low-fat Gruyère cheese, shredded
- 1 tablespoon fresh thyme, finely chopped
- 1 tablespoon fresh rosemary, finely chopped

## Steps

1. Preheat oven to 375°F. Melt unsalted butter substitute and olive oil in 10-inch ovenproof nonstick skillet over medium-high heat.
2. Add leeks to melted butter substitute, stirring to coat. Cook leeks until tender, stirring frequently, 5-6 minutes. Season with salt and pepper.
3. Whisk eggs and milk in a large bowl until combined. Pour eggs into skillet with leeks and sprinkle with low-fat Gruyère, thyme, and rosemary. Gently fold ingredients to combine.
4. Transfer skillet to oven and bake until eggs are just set, 15-18 minutes. Remove from oven and let cool in skillet for 2 minutes. Gently slide frittata onto large plate and cut into wedges to serve.

\*Includes Sandostatin® (octreotide acetate) Immediate-Release Injection and Sandostatin® LAR Depot (octreotide acetate) for injectable suspension for all approved indications.

**Please note that Novartis Pharmaceuticals Corporation does not endorse the use of any foods highlighted in this article; all information is provided for educational purposes only. Use of any food in this recipe is not intended to treat or cure carcinoid syndrome. You are advised to speak to your health care provider before introducing new foods into your diet.**

**Please see Indications and Important Safety Information on page 2.**

Please [click here](#) for full Prescribing Information.

Links to: [https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin\\_lar.pdf](https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin_lar.pdf)

Brought to you by RealSupport™, a patient information and support program for those with the severe diarrhea and flushing of carcinoid syndrome. RealSupport™ is provided by Novartis Pharmaceuticals Corporation, the maker of Sandostatin® LAR Depot (octreotide acetate) for injectable suspension. For more information about RealSupport™ program offerings, please follow us on [www.facebook.com/SandostatinLARDepot](https://www.facebook.com/SandostatinLARDepot).

Links to: <https://www.facebook.com/SandostatinLARDepot>

## INDICATIONS AND USAGE

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

## IMPORTANT SAFETY INFORMATION

**Warnings and Precautions:** Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

**Before Taking Sandostatin LAR Depot:** Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

**Common Side Effects:** Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

**Other Information:** Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](https://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Please [click here](#) for full Prescribing Information.

Links to: [https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin\\_lar.pdf](https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/sandostatin_lar.pdf)

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit [us.sandostatin.com](https://www.us.sandostatin.com)

Links to: <https://www.us.sandostatin.com/>

Links to: <https://www.fda.gov/Safety/MedWatch/default.htm>

